Cash and Short Term Investments (Quarterly) Chart

View Cash and Short Term Investments (Quarterly) for VRTX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Quarterly) Chart
Start Trial

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 7.863B
March 31, 2026 7.259B
December 31, 2025 6.611B
September 30, 2025 6.295B
June 30, 2025 6.393B
March 31, 2025 6.212B
December 31, 2024 6.118B
September 30, 2024 6.533B
June 30, 2024 5.796B
March 31, 2024 10.17B
December 31, 2023 11.22B
September 30, 2023 11.93B
June 30, 2023 11.24B
March 31, 2023 10.42B
December 31, 2022 10.79B
September 30, 2022 9.776B
June 30, 2022 9.258B
March 31, 2022 8.243B
December 31, 2021 7.53B
September 30, 2021 6.965B
June 30, 2021 6.715B
March 31, 2021 6.933B
December 31, 2020 6.660B
September 30, 2020 6.154B
June 30, 2020 5.455B
Date Value
March 31, 2020 4.199B
December 31, 2019 3.816B
September 30, 2019 4.003B
June 30, 2019 3.958B
March 31, 2019 3.478B
December 31, 2018 3.168B
September 30, 2018 3.064B
June 30, 2018 2.776B
March 31, 2018 2.487B
December 31, 2017 2.090B
September 30, 2017 1.814B
June 30, 2017 1.733B
March 31, 2017 1.453B
December 31, 2016 1.497B
September 30, 2016 1.187B
June 30, 2016 1.142B
March 31, 2016 1.102B
December 31, 2015 1.127B
September 30, 2015 1.082B
June 30, 2015 1.105B
March 31, 2015 1.181B
December 31, 2014 1.398B
September 30, 2014 1.478B
June 30, 2014 1.219B
March 31, 2014 1.324B

Cash and Short Term Investments Definition

Represents the sum of cash and short term investments.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
Gilead Sciences, Inc. 4.882B
Alnylam Pharmaceuticals, Inc. 3.308B
Sionna Therapeutics, Inc. 211.03M
Regeneron Pharmaceuticals, Inc. 8.005B
Biogen, Inc. 1.285B